Prometheus Biosciences, Inc.
RXDX
Xếp hạng trong cổ phiếu
#3259
Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused... Prometheus Biosciences, Inc. is a biopharmaceutical company primarily focused on discovering, developing, and commercializing innovative therapeutics and complementary diagnostic products, mainly targeting inflammatory bowel diseases (IBD). Its flagship therapeutic candidate, PRA023, is a humanized IgG1 monoclonal antibody currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for its potential in addressing ulcerative colitis and Crohn's disease, both forms of IBD, as well as systemic sclerosis-associated interstitial lung disease. Beyond its lead asset, Prometheus maintains an active development pipeline featuring several other programs targeting IBD and other immune-mediated conditions: PR600: An anti-tumor necrosis factor monoclonal antibody (mAb) for IBD. PR300: A small molecule G-protein coupled receptor modulator specifically for IBD. PR1100: An anti-cytokine receptor mAb with applications in IBD and various other immune disorders. PR1800: An anti-chemokine mAb focused on IBD. PR2100: An anti-inflammatory cytokine mAb also aimed at IBD. Furthermore, the company has forged key alliances, including a diagnostic development and collaboration pact with Takeda Pharmaceutical Company Limited, a co-development and manufacturing arrangement with Dr. Falk Pharma GmbH, a licensing agreement with Cedars-Sinai Medical Center, and a strategic partnership with Millennium Pharmaceuticals, Inc. Tracing its origins, the company was initially incorporated in 2016 as Precision IBD, Inc., before rebranding to Prometheus Biosciences, Inc. in October 2019. Its corporate headquarters are situated in San Diego, California.
Giá cổ phiếu
$199.92
Đồng bộ lần cuối: 2023-06-15
Vốn hóa thị trường
$5.39B
Thay đổi (1 ngày)
0.09%
Thay đổi (1 năm)
0.00%
Quốc gia
US
Giao dịch Prometheus Biosciences, Inc. (RXDX)
Danh mục
Healthcare
Tỷ lệ P/S của Prometheus Biosciences, Inc. (RXDX)
Tỷ lệ P/S vào October 2026 TTM: 1.40K
Theo các báo cáo tài chính và giá cổ phiếu mới nhất của Prometheus Biosciences, Inc., tỷ lệ P/S hiện tại (TTM) là 1.40K. Vào cuối năm 2021, công ty có P/S là 395.96.
Lịch sử tỷ lệ P/S của Prometheus Biosciences, Inc. từ 2014 đến 2026
Tỷ lệ P/S vào cuối mỗi năm
| Năm | Tỷ lệ P/S | Thay đổi |
|---|---|---|
| 2026 (TTM) | 1.40K | 113.94% |
| 2022 | 656.18 | 65.72% |
| 2021 | 395.96 | -44.40% |
| 2020 | 712.14 | 16.66% |
| 2019 | 610.42 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | 3.09K | 0.00% |
Tỷ lệ P/S của các công ty tương tự hoặc đối thủ cạnh tranh
| Công ty | Tỷ lệ P/S | Chênh lệch Tỷ lệ P/S | Quốc gia |
|---|---|---|---|
| 10.72 | -99.24% |
US
|
|
| 41.70 | -97.03% |
US
|
|
| 4.19 | -99.70% |
AU
|
|
| 5.80 | -99.59% |
BE
|
|
| 10.44 | -99.26% |
NL
|
